Background and purpose: Transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma is characterized by a low rate of necrosis

while

125

I seed implantation

as a new radiotherapy technique

has strong targeting advantages. In this study

we aimed to explore the clinical

efficacy of

125

I seed implantation combined with TACE therapy (combined with lobaplatin as a chemotherapy drug) and 3-year survival of patients with advanced unresectable primary hepatocellular carcinoma

and to provide reference for the clinical treatment. Methods: In the prospective study

102 patients with advanced unresectable primary hepatocellular carcinoma at the Affiliated Tumor Hospital of Zhengzhou University from January 2010 to January 2013 were selected and randomly divided into control group and observation group with 51 cases in each group. Patients in control group were treated with TACE

and the patients in observation group were treated with TACE combined with

125

I particles implantation. The changes of alpha-fetoprotein (AFP)

liver function

cell immune indexes and tumor metastasis and curative effect were observed before and after 6 months of treatment. The clinical effect

3-year survival rate and adverse reactions of the two groups were recorded and compared. Results: There was no statistically significant difference between the two groups of patients in general information and clinical related indicators before the treatment (P0.05). After different treatment procedures

the effective rate of observation group (86.3%) was significantly higher than that of the control group (68.6%); Six months after the treatment

the serum level of AFP was significantly lower in both groups

and the serum AFP content of the observation group was significantly lower than that of the control group (P0.05). There was no statistically significant difference in liver function indexes and cellular immune function indexes before the treatment and after the treatment for 6 months (P0.05). The incidence of distant metastasis in the observation group was 7.8%

significantly lower than that of the control group (23.5%)

survival rates of 1

2 and 3 year were 68.6%

43.1% and 31.4%

which were significantly higher than those of the control group (41.2%

29.4% and 13.7%

P0.05). Both groups had n

o serious complications during the follow-up period. Conclusion: The

125

I seed implantation combined with TACE therapy (combined with lobaplatin as a chemotherapy drug) is more effective in controlling tumor metastasis and improving the survival rate

which is worthy of clinical application.